Oncimmune Holdings PLC - immunodiagnostics firm - Signa an autoantibody profiling collaboration with an undisclosed biopharmaceutical company. The programme, which is scheduled to complete in the second quarter of 2021, will evaluate the autoantibody profiles from patient samples collected in a clinical trial of a immune checkpoint inhibitor. Such profiling is expected to enable the biopharmaceutical partner to identify better the groups of patients likely to both tolerate a particular immune checkpoint inhibitor treatment and also those whose disease is likely to respond positively to that treatment. Under the agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag, to identify tumour associated antibody markers that are predictive of response and immune-related adverse events.
Current stock price: 154.00 pence
Year-to-date change: multiplied
By Evelina Grecenko; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.